Enhanced H. pylori Treatment Using a β‐Cyclodextrin–Propolis Complex: A Randomized Clinical Trial.
Background: Helicobacter pylori infection poses a significant global health burden, with rising antibiotic resistance and treatment‐related side effects highlighting the need for adjunctive therapies. Propolis, a natural resin with known antimicrobial and anti‐inflammatory properties, suffers from p...
| Publicado en: | BioMed Research International Vol. 2026; pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | pictorial research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Wiley-Blackwell
7/7/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195154775&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195154775 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 7/7/2026 vid: 2026 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 195154775 195154775 195154775 10.1155/bmri/6257147 195154775 ppf: 1 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: Enhanced H. pylori Treatment Using a β‐Cyclodextrin–Propolis Complex: A Randomized Clinical Trial. aug: au: Mehri, Aisa Pourmoslemi, Shabnam Khalilian, Alireza Safari, Mahdi Ayubi, Erfan Himangshu, Himangshu affil: Department of Pharmaceutics,, School of Pharmacy,, Hamadan University of Medical Sciences,, Hamadan, Iran, umsha.ac.ir sug: subj: Helicobacter Infections Drug Therapy Glucans Therapeutic Use Glucans Pharmacodynamics Propolis Therapeutic Use Propolis Pharmacodynamics Drug Efficacy Evaluation Drug Delivery Systems Human Iran Female Male Randomized Controlled Trials Random Assignment Control Group Double-Blind Studies Sample Size Determination Microscopy, Electron, Scanning Glucans Administration and Dosage Propolis Administration and Dosage Placebos Particle Size Spectrophotometry, Infrared Adult Middle Age Aged Bismuth Administration and Dosage Amoxicillin Administration and Dosage Metronidazole Administration and Dosage Omeprazole Administration and Dosage Treatment Duration Treatment Outcomes Comparative Studies Drug Resistance, Microbial T-Tests Chi Square Test Fisher's Exact Test Mann-Whitney U Test Data Analysis Software Descriptive Statistics Funding Source Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Female Male ab: Background: Helicobacter pylori infection poses a significant global health burden, with rising antibiotic resistance and treatment‐related side effects highlighting the need for adjunctive therapies. Propolis, a natural resin with known antimicrobial and anti‐inflammatory properties, suffers from poor solubility and bioavailability. This study evaluated a β‐cyclodextrin–propolis complex designed to enhance delivery and therapeutic efficacy in H. pylori‐infected patients. Materials and Methods: In a double‐blind, randomized clinical trial at Hamadan University of Medical Sciences, biopsy‐confirmed H. pylori patients received standard quadruple therapy plus omeprazole. The treatment group (n = 28) also received 250 mg/day of the β‐cyclodextrin–propolis complex for 2 months; the control group (n = 12) received placebo capsules. Outcomes were assessed using fecal antigen tests and gastrointestinal symptom questionnaires 2 months posttreatment. Characterization of the complex was performed using FESEM, FTIR, and drug release profiling in PBS (pH 7.4). Results: The complex demonstrated a successful formation and a sustained propolis release profile. Clinically, 57.1% of treated patients achieved negative antigen tests and symptom resolution, compared with 41.6% in the control group. Adverse effects were mild and comparable between groups. Conclusion: These findings suggest that the β‐cyclodextrin–propolis complex may serve as an effective natural adjunct to standard H. pylori treatment, offering potential benefits in eradication rates and symptom relief. Trial Registration: Iranian Registry of Clinical Trials (IRCT): 20230503058065N1. pubtype: Academic Journal doctype: pictorial research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|